X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6754) 6754
Book Review (2345) 2345
Publication (579) 579
Book Chapter (43) 43
Conference Proceeding (35) 35
Magazine Article (8) 8
Dissertation (5) 5
Book / eBook (3) 3
Reference (2) 2
Data Set (1) 1
Newspaper Article (1) 1
Presentation (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (5910) 5910
humans (4492) 4492
glucagon-like peptide-1 (3600) 3600
animals (2963) 2963
male (2444) 2444
diabetes mellitus, type 2 - drug therapy (2307) 2307
endocrinology & metabolism (2258) 2258
diabetes (1943) 1943
hypoglycemic agents - therapeutic use (1917) 1917
type 2 diabetes (1879) 1879
glucose (1552) 1552
glucagon (1542) 1542
female (1501) 1501
insulin (1433) 1433
pharmacology & pharmacy (1264) 1264
peptides (1198) 1198
mice (1160) 1160
glucagon-like peptide 1 (1124) 1124
glp-1 (1104) 1104
middle aged (1054) 1054
liraglutide (1012) 1012
rats (1012) 1012
obesity (936) 936
blood glucose - metabolism (921) 921
glucagon-like peptide 1 - therapeutic use (879) 879
glucagon-like peptide 1 - analogs & derivatives (863) 863
glycemic control (837) 837
diabetes mellitus (801) 801
glucagon-like peptide 1 - metabolism (771) 771
adult (751) 751
analysis (738) 738
hypoglycemic agents - pharmacology (736) 736
insulin - metabolism (735) 735
exenatide (730) 730
diabetes mellitus, type 2 - blood (725) 725
glucagon-like peptide-1 receptor (718) 718
peptides - therapeutic use (693) 693
dextrose (679) 679
aged (668) 668
research (666) 666
treatment outcome (663) 663
diabetes mellitus, type 2 - metabolism (658) 658
dipeptidyl-peptidase iv inhibitors - therapeutic use (658) 658
physiological aspects (625) 625
abridged index medicus (624) 624
care and treatment (618) 618
secretion (608) 608
rodents (607) 607
insulin resistance (603) 603
blood glucose - drug effects (597) 597
internal medicine (573) 573
insulin secretion (571) 571
hypoglycemic agents - administration & dosage (543) 543
health aspects (542) 542
type-2 diabetes-mellitus (541) 541
hypoglycemic agents (535) 535
venoms - therapeutic use (529) 529
hypoglycemic agents - adverse effects (526) 526
double-blind (511) 511
drug therapy (509) 509
beta-cell function (506) 506
medicine & public health (505) 505
diabetes therapy (502) 502
insulin - blood (500) 500
hyperglycemia (499) 499
metformin (498) 498
peptides - pharmacology (495) 495
physiology (477) 477
metabolism (469) 469
risk factors (464) 464
exendin-4 (442) 442
glucagon-like peptide 1 - pharmacology (439) 439
glucose metabolism (434) 434
receptors, glucagon - agonists (433) 433
glucagon-like peptide 1 - blood (432) 432
digestive, oral, and skin physiology (420) 420
mice, inbred c57bl (419) 419
endocrine system (415) 415
biochemistry & molecular biology (412) 412
insulin-secretion (411) 411
incretins - therapeutic use (408) 408
body weight (402) 402
glucagon-like peptide-1 receptor - agonists (398) 398
drug therapy, combination (393) 393
diabetes mellitus, type 2 - complications (385) 385
diabetes mellitus, type 2 - physiopathology (380) 380
incretin (378) 378
venoms - pharmacology (368) 368
food-intake (364) 364
gastric-inhibitory polypeptide (362) 362
clinical trials (361) 361
expression (356) 356
receptor (354) 354
article (349) 349
medicine, research & experimental (349) 349
rats, sprague-dawley (344) 344
insulin-resistance (341) 341
hormones (339) 339
glucagon-like peptide 1 - agonists (338) 338
review (337) 337
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6583) 6583
German (43) 43
Japanese (27) 27
Spanish (27) 27
French (22) 22
Chinese (13) 13
Czech (13) 13
Italian (9) 9
Danish (8) 8
Polish (8) 8
Hungarian (6) 6
Russian (5) 5
Dutch (4) 4
Korean (3) 3
Portuguese (3) 3
Swedish (3) 3
Bosnian (1) 1
Croatian (1) 1
Finnish (1) 1
Norwegian (1) 1
Romanian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2009, Volume 374, Issue 9683, pp. 39 - 47
Summary Background Unlike most antihyperglycaemic drugs, glucagon-like peptide-1 (GLP-1) receptor agonists have a glucose-dependent action and promote weight... 
Internal Medicine | NON-INFERIORITY | METFORMIN | MEDICINE, GENERAL & INTERNAL | GLYCEMIC CONTROL | SULFONYLUREA | GLUCAGON-LIKE PEPTIDE-1 | HUMAN GLP-1 ANALOG | BETA-CELL MASS | TREATED PATIENTS | ACUTE-PANCREATITIS | INSULIN GLARGINE | Nausea - chemically induced | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Glycated Hemoglobin A - drug effects | Male | Diabetes Mellitus, Type 2 - metabolism | Weight Loss - drug effects | Dose-Response Relationship, Drug | Glucagon-Like Peptide 1 - agonists | Injections, Subcutaneous | Female | Hypoglycemia - chemically induced | Hypoglycemic Agents - therapeutic use | Drug Administration Schedule | Peptides - chemistry | Glucagon-Like Peptide 1 - analogs & derivatives | Venoms - adverse effects | Glucagon-Like Peptide 1 - chemistry | Linear Models | Logistic Models | Treatment Outcome | Hypoglycemic Agents - chemistry | Blood Glucose - drug effects | Analysis of Variance | Venoms - therapeutic use | Venoms - chemistry | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Hypoglycemic Agents - adverse effects | Liraglutide | Peptides - adverse effects | Peptides - therapeutic use | Glucagon-Like Peptide 1 - therapeutic use | Type 2 diabetes | Hypoglycemic agents | Dosage and administration | Drug therapy | Molecular structure | Clinical trials | Diabetes | Clinical medicine | Apoptosis | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2013, Volume 381, Issue 9861, pp. 117 - 124
Journal Article
Diabetes, ISSN 0012-1797, 10/2014, Volume 63, Issue 10, pp. 3346 - 3358
GLP-1 receptor (GLP-1R) is widely located throughout the brain, but the precise molecular mechanisms mediating the actions of GLP-1 and its long-acting analogs... 
NERVOUS-SYSTEM | GLUCOSE-HOMEOSTASIS | ENERGY-EXPENDITURE | GLUCAGON-LIKE PEPTIDE-1 | FOOD-INTAKE | ENDOCRINOLOGY & METABOLISM | WEIGHT-LOSS | RAT-BRAIN | DIET-INDUCED OBESITY | RECEPTORS | TYPE-2 DIABETES-MELLITUS | Protein Kinases - metabolism | Metformin - therapeutic use | Obesity - drug therapy | Humans | Middle Aged | Male | Diabetes Mellitus, Type 2 - metabolism | Eating - physiology | Young Adult | Glucagon-Like Peptide 1 - agonists | Aged, 80 and over | Adult | Female | Hypothalamus - drug effects | Drug Therapy, Combination | Energy Metabolism - physiology | Hypoglycemic Agents - therapeutic use | Glucagon-Like Peptide 1 - analogs & derivatives | Metformin - pharmacology | Glucagon-Like Peptide 1 - pharmacology | Rats | Hypoglycemic Agents - pharmacology | Obesity - metabolism | Peptides - pharmacology | Eating - drug effects | Animals | Hypothalamus - metabolism | Venoms - therapeutic use | Adipose Tissue, Brown - drug effects | Adipose Tissue, Brown - metabolism | Aged | Mice | Venoms - pharmacology | Thermogenesis - drug effects | Diabetes Mellitus, Type 2 - drug therapy | Energy Metabolism - drug effects | Liraglutide | Peptides - therapeutic use | Glucagon-Like Peptide 1 - therapeutic use | Type 2 diabetes | Complications and side effects | Thermogenesis | Body weight | Brown adipose tissue | Development and progression | Research | Risk factors | Tissue | Brain | Obesity | Peptides | Weight | Index Medicus | Abridged Index Medicus
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 07/2013, Volume 15, Issue 7, pp. 642 - 649
Aim Assess the pharmacodynamics of lixisenatide once daily (QD) versus liraglutide QD in type 2 diabetes insufficiently controlled on metformin. Methods In... 
metformin | GLP | receptor | type 2 diabetes | pharmacodynamics | Type 2 diabetes | Pharmacodynamics | GLP-1 | Metformin | Receptor | FASTING PLASMA-GLUCOSE | GLYCEMIC CONTROL | SAFETY | EXENATIDE | OPEN-LABEL | PEPTIDE-1 ANALOG | ENDOCRINOLOGY & METABOLISM | POSTPRANDIAL HYPERGLYCEMIA | DOUBLE-BLIND | GLP-1 RECEPTOR AGONIST | PLACEBO-CONTROLLED TRIAL | Glycated Hemoglobin A - analysis | Metformin - therapeutic use | C-Peptide - blood | Glucagon-Like Peptide 1 - administration & dosage | Humans | Middle Aged | Male | Glucagon - blood | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Injections, Subcutaneous | Adult | Female | Drug Resistance | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Drug Administration Schedule | Hyperinsulinism - prevention & control | Glucagon-Like Peptide 1 - analogs & derivatives | Diabetes Mellitus, Type 2 - blood | Incretins - adverse effects | Aged | Incretins - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Hypoglycemic Agents - adverse effects | Incretins - administration & dosage | Liraglutide | Peptides - adverse effects | Peptides - therapeutic use | Glucagon-Like Peptide 1 - therapeutic use | Care and treatment | Glucagon | Hypoglycemic agents | Glucose | Dextrose | Diabetes therapy | Index Medicus | Original
Journal Article
by Hernandez, Adrian F and Green, Fiona and Green, Jennifer B and Janmohamed, Salim and D'Agostino, Ralph B and Granger, Christopher B and Jones, Michael and Jones, Nigel P and Leiter, Lawrence A and Rosenberg, Anne E and Rosenberg, Anne and Sigmon, Kristina and Sigmon, Kristina N and Somerville, Matthew and Somerville, Matthew C and Thorpe, Karl and Thorpe, Karl M and McMurray, John J V and McMurray, John J.V and Del Prato, Stefano and Califf, Robert M and Holman, Rury and DeMets, David and Riddle, Matthew and Goodman, Shaun and McGuire, Darren and Alexander, Karen and Devore, Adam and Melloni, Chiara and Patel, Chetan and Patel, Rajesh and Patel, Vickas and Patel, Prashant and Patel, Rajivkumar and Kong, David and Bloomfield, Gerald and Roe, Matthew and Tricoci, Pierluigi and Harrison, Rob and Harrison, Lindsay and Lopes, Renato and Mathews, Robin and Mehta, Anand and Mehta, Rajendra and Schuyler Jones, William and Vemulapalli, Sreekanth and Povsic, Thomas and Eapen, Zubin and Dombrowski, Keith and Kolls, Brad and Jordan, Dedrick and Ambrosy, Andrew and Greene, Deb and Greene, Stephen and Mandawat, Aditya and Shavadia, Jay and Cooper, John and Cooper, Lauren and Sharma, Abhinav and Sharma, Richa and Guimaraes, Patricia and Friedman, Daniel and Wilson, Matt and Wilson, Tim and Endsley, Patricia and Gentry, Tracy and Collier, Jeannie and Perez, Kathleen and James, Kourtnei and James, Rachel and Roush, Jennifer and Pope, Connie and Howell, Christina and Johnson, Megan and Johnson, David and Johnson, Andrew and Bailey, Matt and Cole, Joanna and Akers, Teresa and Vandyne, Beth and Thomas, Betsy and Rich, Jenny and Bartone, Susan and Beaulieu, Gail and Brown, Judith and Brown, Kim and Chau, Tuan and Christian, Tamra and Coker, Rebecca and Haddock, Trevorlyn and Jenkins, Wendy and Haque, Ghazala and Marquess, Marsha and Pesarchick, Jean and Rethaford, Renee and Stone, Allegra and Al Kawas, Firas and Anderson, Michelle and Enns, Robert and Sinay, Isaac and ... and Harmony Outcomes Comm Investigator and Harmony Outcomes committees and investigators
The Lancet, ISSN 0140-6736, 10/2018, Volume 392, Issue 10157, pp. 1519 - 1529
Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular... 
MEDICINE, GENERAL & INTERNAL | RISK | METAANALYSIS | MELLITUS | SAFETY | RECEPTOR AGONISTS | Hypoglycemic Agents - therapeutic use | Cardiovascular Diseases - etiology | Stroke - prevention & control | Double-Blind Method | Drug Administration Schedule | Glucagon-Like Peptide 1 - administration & dosage | Glucagon-Like Peptide 1 - analogs & derivatives | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Treatment Outcome | Stroke - etiology | Hypoglycemic Agents - administration & dosage | Injections, Subcutaneous | Adult | Female | Aged | Myocardial Infarction - prevention & control | Diabetes Mellitus, Type 2 - drug therapy | Myocardial Infarction - etiology | Diabetes Mellitus, Type 2 - complications | Glucagon-Like Peptide 1 - therapeutic use | Myocardial infarction | Diabetic retinopathy | Heart attacks | Peptides | Glucagon | Medical services | Clinical trials | Cardiovascular disease | Thyroid gland | Incidence | Thyroid carcinoma | Randomization | Motivation | Hemoglobin | Diuretics | Diabetes mellitus (non-insulin dependent) | Glucagon-like peptide 1 | Thyroid | Cerebral infarction | Stroke | Diabetes mellitus | Pancreatitis | Health risks | Risk reduction | Disease control | Patients | Organic chemistry | Interactive systems | Pancreatic cancer | Fatalities | Infarction | Diabetes | Cardiovascular diseases | Health risk assessment | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article